Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Recombinant Poliomyelitis Vaccine (rPV)

Phase 1

SSerum Institute of India Pvt. Ltd.

1

Indications

1

Total Trials

1

Active Trials

0

Competitors

Pipeline

Status by Indication[2][1]

Indication

Polio ImmunityNot yet recruiting

Polio ImmunityPhase 1

Not yet recruiting

Timeline

Expected Milestones

Q1 2027

Phase 1Not yet recruiting

Polio Immunity

NCT07688369

Clinical

Trials by Indication[1]

Polio Immunity1 trial

A Phase 1, Double-blinded, Randomised, Active Controlled, Clinical Trial to Assess the Reactogenicity, Safety and Immunogenicity of a Recombinant Poliomyelitis Vaccine (rPV) in Comparison With IPOL Vaccine in Healthy Adults

Not yet recruiting·SSerum Institute of India Pvt. Ltd.·Phase 1·NCT07688369·36 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Recombinant Poliomyelitis Vaccine (rPV). U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Recombinant Poliomyelitis Vaccine (rPV). EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Serum Institute of India Pvt. Ltd. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: SSerum Institute of India Pvt. Ltd.

Related News